CD274 and non-small cell lung carcinoma: Based on the findings of this trial, adjuvant atezolizumab is recommended in patients with completely resected, PD-L1-positive, stage II to IIIA NSCLC who received previous adjuvant platinum-doublet chemotherapy (7).